Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes (Q28243911)

26 March 2017

1 reference

Paul M Tulkens

2

0 references

Françoise Van Bambeke

object named as

Françoise Van Bambeke

series ordinal

1

0 references

Paul M Tulkens

series ordinal

2

object named as

Paul M. Tulkens

1 reference

26 March 2017

language of work or name

English

0 references

publication date

2009

1 reference

26 March 2017

1 reference

26 March 2017

volume

32

1 reference

26 March 2017

issue

5

1 reference

26 March 2017

page(s)

359-78

0 references

359-378

1 reference

Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials

26 March 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Adverse cutaneous reactions and drugs: a focus on antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Adverse reactions to fluoroquinolones. an overview on mechanistic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Temafloxacin syndrome: review of 95 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Increase in insulin release from rat pancreatic islets by quinolone antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Hypoglycemia in hospitalized nondiabetic older patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Drug interactions and hepatitis produced by some macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200932050-00001

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

21 January 2018

1 reference

12 December 2020

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

1 reference

12 December 2020

Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis

1 reference

12 December 2020

Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice : evidence from a post-marketing surveillance study of 1467 patients

1 reference

12 December 2020

Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.

1 reference

12 December 2020

The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].

1 reference

12 December 2020

Telithromycin use and spontaneous reports of hepatotoxicity

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment

1 reference

12 December 2020

The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs

1 reference

12 December 2020

A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia

1 reference

12 December 2020

Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice : results of a post-marketing surveillance study

1 reference

12 December 2020

Images in clinical medicine. Quinolone-associated rupture of the Achilles' tendon

1 reference

12 December 2020

Outpatient gatifloxacin therapy and dysglycemia in older adults

1 reference

12 December 2020

Clinical experience with moxifloxacin in patients with respiratory tract infections

1 reference

12 December 2020

Dysglycaemias and fluoroquinolones

1 reference

12 December 2020

Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid

1 reference

12 December 2020

In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity

1 reference

12 December 2020

Sepsis and cholestasis

1 reference

12 December 2020

Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin

1 reference

12 December 2020

Moxifloxacin-induced acute liver injury

1 reference

12 December 2020

Fluoroquinolones and tendon disorders

1 reference

12 December 2020

Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

1 reference

12 December 2020

Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

1 reference

12 December 2020

Fluoroquinolone-associated dysglycemias: a tale of two toxicities

1 reference

12 December 2020

Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

1 reference

12 December 2020

Antimicrobial-associated QT interval prolongation: pointes of interest

1 reference

12 December 2020

Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.

1 reference

12 December 2020

1 reference

12 December 2020

Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells.

1 reference

12 December 2020

Moxifloxacin in respiratory tract infections

1 reference

12 December 2020

Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability

1 reference

12 December 2020

Hepatic adverse drug reactions: a case/non-case study in Italy

1 reference

12 December 2020

Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis

1 reference

12 December 2020

Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure.

1 reference

12 December 2020

Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation.

1 reference

12 December 2020

Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea

1 reference

12 December 2020

Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model

1 reference

12 December 2020

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy

1 reference

12 December 2020

Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy

1 reference

12 December 2020

Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system

1 reference

12 December 2020

Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?

1 reference

12 December 2020

Moxifloxacin and torsade de pointes

1 reference

12 December 2020

Seizures associated with fluoroquinolones

1 reference

12 December 2020

Acute and clinically relevant drug-induced liver injury: a population based case-control study.

1 reference

12 December 2020

An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.

1 reference

12 December 2020

Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003)

1 reference

12 December 2020

Guide to selection of fluoroquinolones in patients with lower respiratory tract infections

1 reference

12 December 2020

Economic aspects of antimicrobial therapy of acute exacerbations of COPD.

1 reference

12 December 2020

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

1 reference

12 December 2020

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

12 December 2020

Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic

1 reference

12 December 2020

Review article: drug hepatotoxicity

1 reference

12 December 2020

Antimicrobial safety: focus on fluoroquinolones

1 reference

12 December 2020

Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis

1 reference

12 December 2020

The safety profile of moxifloxacin and other fluoroquinolones in special patient populations

1 reference

12 December 2020

Drug-induced prolongation of the QT interval

1 reference

12 December 2020

Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy

1 reference

12 December 2020

Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability

1 reference

12 December 2020

Safety concerns with fluoroquinolones

1 reference

12 December 2020

A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium

1 reference

12 December 2020

Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects

1 reference

12 December 2020

Evolution of resistance patterns and identification of risk factors for Streptococcus pneumoniae colonisation in daycare centre attendees in Athens, Greece

1 reference

12 December 2020

Fluoroquinolone adverse effects and drug interactions

1 reference

12 December 2020

A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone

1 reference

12 December 2020

Arrhythmias associated with fluoroquinolone therapy

1 reference

12 December 2020

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

1 reference

12 December 2020

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

1 reference

12 December 2020

Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

1 reference

12 December 2020

Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges

1 reference

12 December 2020

Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors

1 reference

12 December 2020

Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry

1 reference

12 December 2020

Hepatotoxicity by antibiotics: update in 2008

1 reference

12 December 2020

Incidence of drug-induced hepatic injuries: a French population-based study

1 reference

12 December 2020

Cost analyses of community-acquired pneumonia from the hospital perspective

1 reference

12 December 2020

Fluoroquinolone toxicity profiles: a review focusing on newer agents

1 reference

12 December 2020

Fluoroquinolone-associated tendinopathy: a critical review of the literature

1 reference

12 December 2020

Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.

1 reference

12 December 2020

Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic

1 reference

12 December 2020

The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia

1 reference

12 December 2020

Risk of acute liver injury associated with the use of drugs: a multicentre population survey

1 reference

12 December 2020

Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury

1 reference

12 December 2020

Proarrhythmic potential of antimicrobial agents

1 reference

12 December 2020

Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).

1 reference

12 December 2020

Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance

1 reference

12 December 2020

Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain

1 reference

12 December 2020

Comparative tolerability of the newer fluoroquinolone antibacterials

1 reference

12 December 2020

Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection

1 reference

12 December 2020

New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance

1 reference

12 December 2020

Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin

1 reference

12 December 2020

Antimicrobial-associated risk factors for Clostridium difficile infection

1 reference

12 December 2020

A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin

1 reference

12 December 2020

QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome

1 reference

12 December 2020

Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease

1 reference

12 December 2020

Efficacy and tolerability of moxifloxacin in patients with respiratory tract infections treated in general practice: Results of a post-marketing surveillance study.

1 reference

12 December 2020

Tolérance cardiaque de la moxifloxacine: expérience clinique issue d'une large étude observationnelle française en pratique médicale usuelle (étude IMMEDIAT)

1 reference

12 December 2020

Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults

1 reference

12 December 2020

Trovafloxacin-induced acute hepatitis

1 reference

12 December 2020

Guidelines for the management of adult lower respiratory tract infections

1 reference

12 December 2020

Efficacy and tolerability of sequential intravenous/oral moxifloxacin therapy in pneumonia: results of the first post-marketing surveillance study with intravenous moxifloxacin in hospital practice

1 reference

12 December 2020

What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?

1 reference

12 December 2020

Outcome and prognostic markers in severe drug-induced liver disease

1 reference

12 December 2020

Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period

1 reference

12 December 2020

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies

1 reference

12 December 2020

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

1 reference

12 December 2020

Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.

1 reference

12 December 2020

Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis

1 reference

12 December 2020

Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials

1 reference

12 December 2020

Population genetics and antibiotic susceptibility of invasive Haemophilus influenzae in Manitoba, Canada, from 2000 to 2006.

1 reference

12 December 2020

Quinolone-associated tendonitis: a potential problem in COPD?

1 reference

12 December 2020

Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice

1 reference

12 December 2020

Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).

1 reference

12 December 2020

Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids

1 reference

12 December 2020

Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections

1 reference

12 December 2020

Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics

1 reference

12 December 2020

Susceptibility of European beta-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003.

1 reference

12 December 2020

Adverse drug reactions: implications for the development of fluoroquinolones

1 reference

12 December 2020

Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens

1 reference

12 December 2020

Cellular basis of drug-induced torsades de pointes

1 reference

12 December 2020

Hypoglycemia as a predictor of mortality in hospitalized elderly patients

1 reference

12 December 2020

Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data

1 reference

12 December 2020

Acute eosinophilic hepatitis from trovafloxacin

1 reference

12 December 2020

Drug interactions during therapy with three major groups of antimicrobial agents

1 reference

12 December 2020

Criteria of drug-induced liver disorders. Report of an international consensus meeting

1 reference

12 December 2020

The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury

1 reference

12 December 2020

Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.

1 reference

12 December 2020

A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia

1 reference

12 December 2020

Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany

1 reference

12 December 2020

Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia

1 reference

12 December 2020

Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study

1 reference

12 December 2020

Assessment of drug-induced liver injury in clinical practice

1 reference

12 December 2020

Drugs, hERG and sudden death

1 reference

12 December 2020

Quinolones in 2005: an update.

1 reference

12 December 2020

Recurrent tendinitis after treatment with two different fluoroquinolones

1 reference

12 December 2020

Suspected drug-induced liver fatalities reported to the WHO database

1 reference

12 December 2020

Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient

1 reference

12 December 2020

Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin

1 reference

12 December 2020

Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice

1 reference

12 December 2020

QT prolongation with antimicrobial agents: understanding the significance

1 reference

12 December 2020

10.2165/00002018-200932050-00001

Identifiers

DOI

2 references

26 March 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1000910883

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19419232

1 reference

Consolidated OpenCitations Corpus – April 2017